「in vitroinvivoin vitroinvivo」の検索結果
165件：66～70件目を表示
-
nt: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmace...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
Production | About Senju | SENJU Pharmaceutical
Trusted pharmaceutical products are created using the latest and best equipment in the environment with rich humanity. As ophthalmic solutions are required to meet the same quality standards as inject...
http://www.senju.co.jp/english/about/production.html -
クロモグリク酸Na点眼液2%「センジュ」
2. 包装 プラスチック点眼容器 5mL×10 23. 主要文献 1） 内田幸男 他：眼科臨床医報, 1981；75：725-746 2） Cox JSG：Disodium Cromoglycate in Allergic Airways Disease. In：Pepys J, Frankland AW, editors. London： Butterworths, 1970：13-25 3） ...
https://www.senju.co.jp/system/files/product_other_file/2023-10/cromoglicate_202302_C3.pdf -
Business Activities | About Senju | SENJU Pharmaceutical
the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in ophthalmic pharmaceuticals. In the hope of developing even more original new products fo...
http://www.senju.co.jp/english/about/business/ -
产品开发方针 | 研究与开发 | 千寿制药株式会社
0亿人尚未得到必要的治疗。报告还指出，导致全球视觉障碍或失明的主要原因包括 白内障、屈光不正（近视，老视等）、年龄相关性黄斑变性、青光眼、糖尿病视网膜病变等。 为创造针对眼部疾病的高价值（First in Class、Best in Class、 提升患者便利性等）产品，我们将继续全力推进研究开发活动。在产品战略上，我们将“为导致视觉障碍或者失明的眼部疾病做出贡献” 、“满足未满足的医疗需求*”以...
http://www.senju.co.jp/chinese/rd/policy/